聚乙烯醇辅助治疗中央型肺癌的疗效和安全性评估  

Evaluation of clinical efficacy and safety of polyvinyl alcohol in adjuvant treatment of central lung cancer

作　　者：梁卫明 梁克 谢锐 黄昕 陈建业 Liang Weiming, Liang Ke , Xie Rui , Huang Xin , Chen Jianye(Interventional Ward , Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, Chin)

机构地区：[1]广东医科大学附属医院介入病区,湛江524000

出　　处：《新医学》2018年第8期575-578,共4页Journal of New Medicine

摘　　要：目的研究聚乙烯醇辅助治疗中央型肺癌的疗效和安全性。方法纳入70例中央型肺癌患者作为研究对象,分为观察组和对照组,每组各35例。观察组行经微导管灌注化学治疗再进行聚乙烯醇栓塞治疗,对照组行常规支气管动脉内灌注化学治疗。比较2组近期疗效和安全性,随访记录2组患者远期预后。结果 2组患者介入治疗均获得成功,观察组治疗后近期总体疗效优于对照组(P<0.05),组间不良反应发生率比较差异无统计学意义(P>0.05)。治疗结束后5年,观察组的生存率为23%(8/35),生存时间(22.8±7.7)月,无进展生存率11%(4/35),无进展生存时间(18.3±5.7)月;对照组的生存率为17%(6/35),生存时间(19.0±8.1)月,无进展生存率9%(3/35),无进展生存时间(15.3±6.2)月。2组总生存率和无进展生存率比较差异均无统计学意义(P均>0.05)。结论聚乙烯醇经微导管栓塞治疗中央型肺癌近期疗效好,安全性高,但其对改善患者远期生存率的效果有限。Objective To evaluate the clinical efficacy and safety of polyvinyl alcohol in the adjuvant treatment of central lung cancer. Methods Seventy patients with centrol lung cancer were enrolled and randomly divided into the observation group （n=35） and control group （n=35）. in the observation group, perfusion chemotherapy via a microcatheter was performed, followed by polyvinyl alcohol embolization, in the control group, routine bronchial intra-arterial peffusion chemotherapy was adopted. The short-terln clinical efficacy and safety were statistically compared between two groups. The long-term clinical prognosis was recorded in two groups. Results The interventional treatment was successfully completed in two groups. The short-terln over-all clinical efficacy in the observation group was significantly better than that in the control group （P 〈 0. 05）, whereas the incidence of adverse events did not significantly differ between two groups （P 〉0. 05）. in the observation group, the 5-year survival rate was 23% （8/35）, the average survival time was （22. 8 ± 7.7） months, the progression-free survival rate was 11% （4/35） and the progression-free survival time was （18.3 ± 5.7） months, in the control group, the 5-year survival rate was 17% （6/35） , the survival time was （19.0±8.1） months, the progression-free survival rate was 9% （3/35） and the progression-free sunvival time was （ 15.3± 6.2） months. The overall survival rate and progression-free sunvival rate did not significantly differ between two groups （both P 〉 0.05）. Conclusion Polyvinyl alcohol embolization via a microcatheter yields high short-terln clinical efficacy and safety in the treatment of central lung cancer, which exerts lomited effect upon the long-term survival rate of patients.

关 键 词：聚乙烯醇 微导管栓塞 中央型肺癌 

分 类 号：R734.2[医药卫生—肿瘤]